Lantheus Holdings, Inc. reports news on its radiopharmaceutical business, including diagnostic imaging agents, radiotherapeutic assets, regulatory decisions and financial results. The company organizes revenue around Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships and Other Revenue, with products used by hospitals, independent imaging centers, government facilities and distribution partners in the United States and abroad.
Recurring updates include quarterly earnings, business guidance, FDA activity for products such as PYLARIFY TruVu, PYLARIFY, Lutetium Lu 177 Dotatate (PNT2003) and LNTH-2501, share repurchases, investor presentations and strategic updates involving radiodiagnostics and radiotherapeutic programs.
Lantheus Holdings (NASDAQ: LNTH) announced data from the CONDOR pivotal trial on piflufolastat F 18 (18F-DCFPyL), presented at the Virtual Society of Nuclear Medicine and Molecular Imaging meeting. Dr. Steven Rowe from Johns Hopkins University delivered an oral presentation on June 15, 2021, analyzing disease detection rates and positive predictive values (PPV) in men with biochemically recurrent prostate cancer. The trial revealed high PPV and median detection rates for various anatomic regions, validating PYLARIFY's efficacy in detecting metastatic lesions.
Lantheus has received FDA approval for PYLARIFY, the first PSMA-targeted PET imaging agent for prostate cancer, marking a major advancement in oncology diagnostics. The agent enhances detection of suspected metastasis and recurrence, enabling timely treatment decisions. PYLARIFY is anticipated to be available across the U.S. by year-end following its immediate rollout in select regions. The approval is supported by pivotal studies showing high specificity and localization rates, making PYLARIFY a vital tool for managing prostate cancer.
Lantheus Holdings (NASDAQ: LNTH) announced a poster presentation of data from its Phase 3 CONDOR study at the ASCO Virtual Meeting from June 4-8, 2021. The session will focus on PSMA-targeted imaging in patients with biochemically recurrent prostate cancer, highlighting the correct localization rate and positive predictive value.
Presenter Frederic Pouliot, M.D., Ph.D., from CHU de Québec-Université Laval will showcase abstract No. 5023. Lantheus is a leader in imaging diagnostics and therapeutics, providing a broad portfolio aimed at serious medical conditions.
Lantheus Holdings (NASDAQ: LNTH) has announced that Mary Anne Heino, President and CEO, along with Bob Marshall, CFO, will present at the Jefferies Virtual Healthcare Conference on June 3 at 10:30 a.m. ET. Investors can access the live webcast of the presentation on the Company’s website. A replay will be available for 30 days post-event. Lantheus is a leader in imaging diagnostics and therapeutics, providing products like DEFINITY® and RELISTOR® to address serious medical conditions.
Lantheus Holdings (NASDAQ: LNTH) reported Q1 2021 revenue of $92.5 million, marking a 2.0% increase from Q1 2020. Net income rose to $9.0 million, equivalent to $0.13 per diluted share, compared to $3.3 million or $0.08 last year. However, adjusted diluted EPS fell 86.3% to $0.05 from $0.36. Operating cash flow was $9.8 million, and free cash flow increased to $7.3 million.
The company updates its FY 2021 revenue guidance to $390 million - $400 million and Q2 revenue between $93 million - $97 million.
EXINI Diagnostics AB, a subsidiary of Lantheus Holdings (NASDAQ: LNTH), has received CE Mark clearance for its AI-based software, aPROMISE, in Europe. This innovative tool enhances quantitative assessment of PSMA PET/CT in oncology, demonstrating a high reproducibility with an intraclass correlation coefficient of 0.99. aPROMISE aims to improve efficiency and accuracy in imaging assessments, particularly in detecting prostate cancer. With potential U.S. approval expected later this year, aPROMISE is designed to strengthen Lantheus's portfolio and assist clinicians in patient management.
Lantheus Holdings (NASDAQ: LNTH) announced a collaboration with Allegheny Health Network (AHN) to develop a treatment for xerostomia using Lantheus' microbubbles combined with AHN's ultrasound-assisted non-viral gene transfer (UAGT) technology. Xerostomia, often caused by cancer treatments, leads to severe dry mouth and related health issues. The partnership aims to leverage UAGT's potential for long-term xerostomia relief, with Lantheus supplying microbubbles. AHN will handle the development and commercialization of the treatment.
Lantheus Holdings, Inc. (NASDAQ: LNTH) has announced its upcoming conference call and webcast scheduled for May 4, 2021, at 8:00 a.m. ET, to discuss the financial and operational results for Q1 2021. Interested parties can join by dialing the provided numbers or through the company's website. Lantheus is known for its innovative imaging diagnostics and therapeutics, including products like DEFINITY® and TechneLite®. The company is headquartered in North Billerica, Massachusetts, with operations in multiple locations.
Lantheus Holdings (NASDAQ: LNTH) announced the hiring of Dr. Bela Denes and Dr. Iryna Teslenko, both reporting to Chief Medical Officer Istvan Molnar, MD. Dr. Denes brings 25 years of urology experience and industry expertise from Amgen and Blue Earth Diagnostics, while Dr. Teslenko has over 17 years in drug development and clinical research in oncology, previously with GlaxoSmithKline. Their combined expertise aims to advance Lantheus' pipeline, particularly in prostate cancer radiopharmaceuticals, reinforcing the company’s commitment to innovative diagnostics and therapeutics.
Lantheus Holdings (NASDAQ: LNTH) has announced the retirement of Michael P. Duffy, General Counsel, effective June 4, 2021, after over 13 years with the company. Duffy will continue in an advisory role, with Daniel Niedzwiecki taking over his responsibilities. Duffy expressed pride in his contributions to the transformation of Lantheus into a publicly traded company since its IPO in 2015, noting a sevenfold increase in market cap. The transition comes on the heels of the successful integration of the Progenics acquisition.